Journal of Contemporary Health Law & Policy (1985-2015)
Volume 29

Issue 1

Article 5

2012

Protecting a Vulnerable Population with Little Regulatory
Framework: A Comparative Analysis of International Guidelines
for Pediatric Research Ethics
Heather L. Mullins-Owens
Macey L. Henderson
Jason Henderson

Follow this and additional works at: https://scholarship.law.edu/jchlp

Recommended Citation
Heather L. Mullins-Owens, Macey L. Henderson & Jason Henderson, Protecting a Vulnerable Population
with Little Regulatory Framework: A Comparative Analysis of International Guidelines for Pediatric
Research Ethics, 29 J. Contemp. Health L. & Pol'y 36 (2013).
Available at: https://scholarship.law.edu/jchlp/vol29/iss1/5

This Article is brought to you for free and open access by CUA Law Scholarship Repository. It has been accepted
for inclusion in Journal of Contemporary Health Law & Policy (1985-2015) by an authorized editor of CUA Law
Scholarship Repository. For more information, please contact edinger@law.edu.

PROTECTING A VULNERABLE POPULATION
WITH LITTLE REGULATORY FRAMEWORK: A
COMPARATIVE ANALYSIS OF INTERNATIONAL
GUIDELINES FOR PEDIATRIC RESEARCH ETHICS
HeatherL. Mullins-Owens, J.D., Macey L. Henderson, iD., andJason
Henderson, D.O., JD.*

Research ethics guidelines in developing nations are a topic of great
importance to a multi-disciplinary audience, and much has been written
about these guidelines from clinical, legal, and ethical perspectives.
However, there is little literature which provides international guidelines for
vulnerable populations such as children and adolescents. Oftentimes, there
are no clear, concise guidelines for inclusion of children and adolescents in
research, and guidelines must be assumed or gleaned from normative ethics
and theories in the form of principles. This Note will begin with an
overview of research ethics rules and regulations as utilized in the United
States, followed by an introduction to three primary concepts in pediatric
research ethics: the assent process for children, placebo use, and defining
minimal risk. After a general introduction to these concepts, we will explore
practical applications of these themes within an international framework.
China, Kenya, and India, will serve as examples of how pediatric research in
developing nations is lightly directed by regulatory guidelines and how
research is impacted by local culture.
I. INTRODUCTION TO U.S. BIOMEDICAL RESEARCH REGULATIONS AND
GUIDELINES

Throughout the majority of U.S. history, children were widely involved in
medical research. Researchers often used their own children in research,
solicited orphans, or used the children of servants or slaves.' After the
publication of Henry K. Beecher's seminal article in 1966 titled "Ethics and
Clinical Research," 2 medical research involving children was strongly

*

We also thank Christine Sego Caldwell, who assisted with editing the citations.
1. See Barbara Conrad

& Sharon Homer, Issues in Pediatric Research:

Safeguarding the Children, 2 J. FOR SPECIALISTS IN PEDIATRIC NURSING 163, 163-64

(1997).
2.

See generally Henry K. Beecher, Ethics and Clinical Research, 274 NEw ENG. J.

MED. 1354 (1966).
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discouraged in an attempt to protect children from harm. While the
Nuremburg Principles of Research Ethics had been available for nearly two
decades, most researchers did not find them readily applicable or relevant to
the medical research being conducted in U.S. institutions.3 The sentiments
expressed in the Beecher article eventually led to medical research
regulations governing inclusion of children in research in the 1970s.
Since the 1990s, however, there has been growing concern that these
regulations restrict children's participation in research resulting in
"therapeutic orphans" (a term coined by Harry C. Shirkey, referring to the
lack of studies exhibiting the safety, dosing, and efficacy for drugs used
routinely in pediatric populations which were approved only for adults).
Eventually, it became evident that excluding children from medical research
inhibited their future access to innovative improvements in care and
treatments. As such, medical researchers and pharmaceutical companies in
the United States and European Union have been strongly encouraged to
increase the number of pharmaceutical trials open to children. Participation
by children in these countries is viewed more as a right to access ethical
medical trials, rather than a need to protect children from research. 5 It is
estimated that 75% of drugs prescribed to children lack "adequate testing in
children." 6 With so many drugs not adequately tested for safety and
effectiveness in children, determining the appropriate dosing for minors is
reduced to educated guesswork.
More clinical studies are being conducted in new regions to achieve
recruitment targets and address the highly competitive search for patients in
conventional territories such as the United States and Western Europe.
There has been a significant increase in the number of pediatric studies
conducted in these nonconventional regions, such as the People's Republic

3.

Lainie Friedman Ross, Informed Consent in PediatricResearch, 13 CAMBRIDGE
346 (2004).

Q. HEALTHCARE ETHICS 346,

4. Harry C. Shirkey, Therapeutic Orphans 1970, 121 J. OF INFECTIOUs DISEASES
348, 348-50 (1970).
5. David Wendler, et al, Quantifying the Federal Minimal Risk Standard:
Implications for Pediatric Research Without a Prospect of Direct Benefit, 294 J. AM.
MED. Ass'N 826, 826 (2005).

6.

Id.

7. Phillippa Smit-Marshall, Pediatric Trials: A World- View, 19 APPLIED CLINCAL
TRIALS, no. 1, 2010 at 32.

The Journalof Contemporary Health Law and Policy

38

Vol. XXIX: 1

Kenya has also become a key market for
of China and India.
pharmaceutical research, including the development of drugs to treat HIV
and AIDS.
Given the growth of the research market in these countries, it is important
for medical professionals, ethicists, and health policy analysts to understand
the particular challenges of conducting research on children in these
markets, and for collaborative relationships and practices to develop in these
markets. Collaboration has already begun among some of the traditional
markets, such as the U.S., Japan, and Europe, through collaborative
institutional relationships and practices.
II. INFORMED CONSENT AND ASSENT PRACTICES AND REGULATIONS IN THE
UNITED STATES

The Belmont Report was created by the National Commission for the
Protection of Human Subjects of Biomedical and Behavioral Research in
1979 and requires that research involving human subjects provide respect for
persons. 9 This principle requires two important moral requirements:
acknowledgement of autonomy when it exists and the protection of the
subject when autonomy is diminished. 10 To respect subject autonomy, the
subject must be provided with all relevant information about the risks,
potential benefits, and requirements for participation in the research. This
process of obtaining informed consent has been defined as an "interactive
process between subject and researcher involving disclosure, discussion, and
a complete understanding of a proposed research activity, which culminates
in the individual freely expressing a wish to participate."" In the United
States, informed consent has its roots in Schloendorff v. Society ofNew York

Hospital (1914), in which a patient sued her doctor for performing an

8. Id.
9.

NAT'L COMM'N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND

BEHAVIORAL RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES

FOR THE PROTECTION OF HUMAN SUBJECTS 4 (1979), available at http://www.recerca.uab.

es/ceeah/docs/Belmont%20Report.pdf.
10. Alexander A. Kon, Assent in PediatricResearch, 117 PEDIATRICS 1806, 1806
(2006).
11.

Julie B. Meaux & Pegge L. Bell, Balancing Recruitment and Protection:

Children as Research Subjects, 24 ISSUES IN COMPREHENSIVE PEDIATRIC NURSING 241,

243 (2001).
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unauthorized surgical procedure. 12 In the decision, Justice Benjamin
Cardozo wrote that:
Every human being of adult years and sound mind has a right to
determine what shall be done with his own body; and a surgeon
who performs an operation without his patient's consent commits
an assault, for which he is liable in damages... This is true, except
in cases of emergency where the patient is unconscious, and where
it is necessary to operate before consent can be obtained.' 3
Additional cases and historical events followed, which reinforced the idea
that doctors must disclose all relevant information for patients to make
informed decisions and must obtain permission from the patient before
proceeding with treatment or research.'
In the United States, only a fully autonomous person can give consent.
Therefore, minors cannot legally provide consent, s and informed consent
to participate in research must be sought from the minor's parents or
guardians. 16 This parental consent amounts to mere permission, since it
grants the researcher permission to request the child's participation in the
research.
Assent may be defined as "a child's informed agreement to the conditions
of participation."' 7 There is less consistency in how, when, and from whom
assent is obtained in U.S. research studies because federal regulations leave
many of the decisions up to the local Institutional Review Boards (IRBs).18
Differing age requirements for assent are common, but generally children

12.

Schloendorffv. Soc'yofN.Y. Hosp., 105 N.E. 92,93(1914).

13.

Id.

14. Canterbury v. Spence, 464 F.2d 772, 780 (D.C. Cir. 1972); Salgo v. Leland
Stanford Jr. Univ. Bd. of Tr., 317 P.2d 170, 181 (Cal. Dist. Ct. App. 1957); 2 Trials of
War Criminals Before the Nuernberg Military Tribunals Under Control Council Law No.
10, at 181 (1947).
15.

45 C.F.R. § 46.402 (2009); Meaux & Bell, supra note 11, at 243.

16.

45 C.F.R. § 46.408.

17. Meaux & Bell, supra note 11, at 243-44; Barbara Conrad & Sharon Homer,
Issues in Pediatric Research: Safeguarding the Children, 2 J. FOR SPECIALISTS IN
PEDIATRIC NURSING 163, 164 (1997).

18.

See generally 45 C.F.R. § 46 (2009).
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sevenl9 or older are asked to assent. Minors of this age typically have the
capacity to understand (albeit often in non-scientific terms) what type of
procedure they will undergo, and how it may differ from the care they would
receive if they were not involved in research. 20 For a child's assent to be
valid, all information about the research must be disclosed in
developmentally appropriate and comprehensible language to the child.21 A
child's dissent to participate supersedes a parent's consent to research
22
Assent by children is typically affected by two types of
participation.
factors: individual factors, such as age, developmental level, and health
status; and environmental factors, such as role constraints, family factors,
differences in education between investigators and community members,
23
access to non-research related health services, and consent-seeker factors.
It should be noted, however, that this focus on autonomy is based on a
we stem concept of personhood, 24 which has its origins in the work of
Western philosophers, such as Emmanuel Kant, who said that "all rational
beings have the capacit to act in a consistent moral manner and they should
be allowed to do so." 2 This point that everyone has a right to make their
own decisions and that these decisions are to be protected and respected by
others, was central to the Belmont Report, and remains central to the
contemporary U.S. notions of autonomy and informed consent.26
19.

Seven is the age recommended by the 1977 National Commission for the

Protection of Human Subjects of Biomedical and Behavioral Research.

See NAT'L

COMM'N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND BEHAVIORAL

RESEARCH, PUB. No. 77-0004, RESEARCH INVOLVING CHILDREN 13 (1977), available at

http://videocast.nih.gov/pdflohrp-research involvingchildren.pdf.
20. See Amy Whittle, et al., IRB PracticesRegarding Assent in PediatricResearch,
113 PEDIATRICS 1747 (2004).

21.

Meaux & Bell, supra note 11, at 243-44.

22.

Id.

23.

Id. at 244.

24. Douglas P. Olsen, Honghong Wang & Samantha Pang, Informed Consent
Practicesof Chinese Nurse Researchers, 17 NURSING ETHICS 179, 179 (2010).
25.

Michael Cheng-tek Tai & Chung Seng Lin, Developing a Culturally Relevant

Bioethicsfor Asian People, 27 J. OF MED. ETHICS 51, 52 (2001).

26. Id.
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Ill. PLACEBO USE

Medical practice in children is quite different than in adults. While most
studies are performed using adult populations, adult populations require
different doses of medication, lengthier follow-ups, and the risk of long-term
adverse events during development and sexual maturity. 27 The efficacy of a
drug in children is usually extrapolated from studies in adults, but not the
safety and dosage. Thus, age of the child and the parents' demand for the
best therapeutic options for their child create special obstacles for exercising
the ethical principle of autonomy.29 The use of placebos in controlled trials
has been and continues to be controversial. The 2008 version of the
Declaration of Helsinki restricts use of placebo trials to those where there is
no current treatment and there is sound rationale for its use.30 In such cases,
the patient receiving a placebo, or even no treatment, should not be subject
to risk or harm. 31
Placebos may also be used when they are
methodologically necessary to determine the efficacy of an intervention.3 2
Ethical Guidelines of the Council for International Organizations of
Medical Sciences (CIOMS) proffered specific guidelines for the use of
placebos in pediatric populations: (1) When there is not a commonlyaccepted treatment for the condition and the medication under study is the
only medication that can modify the course of the disease's progression; (2)
When the commonly-used treatment for the condition is of questionable
efficacy; (3) When the commonly-used treatment for the condition has
undesirable side effects and the risks of use can be significantly greater than
the benefits; (4) When the placebo is used to identify the incidence and
severity of undesirable side effects produced (when adding a new treatment
to an established regimen); or (5) When the disease is characterized by an

27. Committee on Drugs, Guidelinesfor the Ethical Conduct of Studies to Evaluate
Drugs in PediatricPopulation, 95 PEDIATRICS 286, 286 (1995).
28.

Vincent Yeung, Chapter 6: Clinical Trials in Children, in PEDIATRIC DRUG

HANDLING 85, 85-86 (Alexander T. Florence & Anthony C. Moffat ed., 2007).
29.

See Whittle, et al., supra note 20.

30.

K. S. Puri, et al., DeclarationofHelsinki, 2008: Implicationsfor Stakeholders in

Research, 55 J. POSTGRAD MED. 131, 133 (2009).

31.

P. P. De Deyn & R. D'Hooge, Placebos in ClinicalPractice andResearch, 22 J.

MED. ETHICS 140, 141 (1996).

32.

Puri et al., supra note 30, at 133.
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increase in frequency, exacerbations or spontaneous remission and the
efficacy of the treatment has not been proven.
Federal regulations in the United States provide no reference to the use of
placebos in pediatric populations, so the CIOMS guidelines for placebo use
are firmly recognized as guiding authority. 34 It has been suggested that each
intervention, placebo, and drug should be assessed for a risk-benefit profile
both separately and collectively.35 Without much specific guidance on what
constitutes certain risk profiles, ethical placebo-controlled, pediatric trials
will have to comply with both the above-mentioned placebo intervention and
the drug intervention guidelines.36
IV. DEFINING MINIMAL RISK IN PEDIATRIC RESEARCH

How is minimal risk defined in pediatric research in the United States?
The Code of Federal Regulations (C.F.R.) defines minimal risk as "the
probability and magnitude of harm or discomfort anticipated in the research
are not greater in and of themselves than those ordinarily encountered in
daily life or during the performance of routine physical or psychological
examinations or tests."3 7 In 2002, The Institute of Medicine called for a
more risk-based review process so that studies posing "minimal risk"
"should be handled diligently, but expeditiously, while studies involving
high risk should receive the extra time and attention they require." 3 8
The United States federal regulations do not further specify the risks of
daily life. Nor do they define what constitutes a "direct" benefit or a "minor
increase" over minimal risk. 39 Accordingly, whether children are enrolled in
33. COUNCIL FOR INT'L ORGS. OF MED. Scis. AND THE WORLD HEALTH ORG.,
INTERNATIONAL ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING HUMAN
SUBJECTS, guideline 11 (2002).

34. Paula L. Knudson, Ethical Issues in Human Subject Research with Children, 33
ARCH. MED. RES. 203, 203 (2002).
35. Franklin G. Miller, et al., When Do the Federal Regulations Allow PlaceboControlled Trials in Children?, 142 J.PEDIATRICS 102, 104 (2003).
36.

Id. at 106.

37.

45 C.F.R. § 46.102(i) (2009).

38.

RESPONSIBLE RESEARCH: A SYSTEMS APPROACH TO PROTECTING RESEARCH

PARTICIPANTS 11 (Daniel D. Federman, et al. eds., National Academies Press 2003).

39.

45 C.F.R. § 46.102(i).
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clinical research only when the risks are low, and whether the clinical
research offers the potential for individual benefit, depends on how a
particular Institutional Review Board (IRB) applies the federal risk and
benefit categories. 40 When assessing whether research participation offers
the pediatric patient a sufficient individual benefit to justify the risks, the
federal regulations direct IRBs to consider only "direct" benefits to pediatric
participants. 4 1 The IRB guidebook notes, however, that "[d]irect payments
or other forms of remuneration offered to potential subjects as an incentive
or reward for participation should not be considered a 'benefit' to be gained
from research."4 2 To minimize the potential for exploitation in research, the
"minimal" risk standard should be interpreted as referring to risks in daily
lives of "typical" children; 43 minimal risk should be defined as the
probability and magnitude of harms that are normally encountered in the
daily life of the general population.44
V. CHINESE REGULATIONS BACKGROUND FOR HUMAN SUBJECTS
RESEARCH

A. Overview of the Regulations and Guidelinesfor EthicalHuman Subjects
Research

The Chinese bioethics landscape offers a rapidly developing and
sometimes overlapping array of regulations and guidelines to be followed
over clinical research. As research funding from the Chinese government
increased in the past decade, the requirement for ethical review of protocols
increased as well. 4 5 The development of China's State Food and Drug
Administration (SFDA) in 2003 helped harmonize varying clinical research

40. Seema Shah, et al., How Do Institutional Review Boards Apply the FederalRisk
and Benefit Standardsfor PediatricResearch?, 291 J. AM. MED. Ass'N 476, 476 (2004).
41.

Id.at 477.

42.

OFFICE FOR THE PROT. FROM RESEARCH RISKS, PROTECTING HUMAN RESEARCH

SUBJECTS: INSTITUTIONAL REVIEw BOARD GUIDEBOOK 3-8 (1993).

43.

Loretta M. Kopelman, Children as Research Subjects: A Dilemma, 25 J. MED.

PHIL. 745, 750 (2000).

44.

Id.

45.

Ruotao Wang & Gail E. Henderson, Medical Research Ethics in China, 372

LANCET 1867, 1867 (2008).
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standards.46 It also increased transparency in the drug approval process.
In its inaugural year, the SFDA issued Good Clinical Practice (GCP)
standards, which clearly defined Contract Research Organizations (CROs)
48
and stipulated that CROs could conduct clinical trials for their clients.
Finally, in 2007, the Ministry of Health (MOH) enacted Regulations on
Ethical Reviews of Biomedical Research Involving Humans, ("2007
Regulations").
Ethical review of all human subjects trials in China are required to comply
with the principles of the Declaration of Helsinki and Council for
International Organizations of Medical Sciences (CIOMS) Guidelines,
according to Clinical Drug Trial Guidelines. 49 Chinese law additionally
requires that investigators comply with all Good Laboratory Practice (GLP)
and GCP Guidelines in all pre-clinical and clinical drug trials. so GCP
governs clinical trials in China and the regulation provides more specific
procedural requirements than the other Chinese regulations considered here.
This principle-based framework has been criticized for possible ethical
imperialism because the focus on individual autonomy seems at odds with a
culture which has emphasized social harmony over individual autonomy for
51
centuries. China is not alone, as many developing countries have virtuebased ethics. 52 This focus on relationships is also seen in Western concepts
of feminist bioethics.
The Chinese MOH is primarily responsible for providing ethical
guidelines for research involving human subjects. The Chinese Academy of
46. Roza Hayduk, et al., Identifying Opportunities and Overcoming Challenges in
ConductingAlzheimer's Disease Trials in Low and Middle Income Countries, QUINTILES
(2010), available at http://www.pharma-mag.com/Portals/OAVhitepapers/Quintiles_
WhitePaper.pdf.
47.

Id.

48.

Clinical Trials in China, RJS MEDICAL TECHNOLOGY INC., http://www.sfdachina.

com/info/91-1.htm (last visited Nov. 12, 2012).
49.

MED. RESEARCH COUNCIL, CHINA-UK RESEARCH ETHICS (CURE) COMMITTEE

REPORT 24 (2009), available at http://www.mrc.ac.uk/Utilities/Documentrecord/index.
htm?d=MRC006303 [hereinafter CURE COMMITEE REPORT].

50.

Id. at 12.

51.

Wang & Henderson, supra note 45, at 1867.

52.

Id.
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Medical Sciences (CAMS) and China Center for Disease Control and
Prevention (CDC) operate under the MOH, which also funds bioethics
research. The SFDA has also been under MOH control since 2008 (a
change of policy to create more governance of the agency after a 2007
scandal involving the director, Zheng Xiaoyu, who was arrested and
executed on corruption charges). Since moving under SFDA control, the
agency has been given increasingly positive press for establishing more
supervision of its policies and leadership, and seems to have "radically
reformed."
B. Ethical Review ofResearch in China

China has followed the U.S. model of IRBs, referred to in China as Ethics
Committees (ECs), which makes the process of approving clinical trials
similar to the process in the United States.54 The SFDA has roughly 40,000
employees, and is responsible for food safety and regulation, medicinal
All proposed clinical trials are
product and medical device regulations.
reviewed by the SFDA, and trials must be conducted at a certified center. 5 6
China has approximately 160 certified centers, open to random inspections
by the SFDA.
Similar to the IRBs in the United States, the ECs review
clinical trials, and can approve, deny, or require modifications of the
presented proposals.5 The ECs are required by the 2007 Regulations to
include at least five people for five-year renewable terms. 5 The SFDA
Clinical Drug Trial Guidelines require the ECs to include male and female
non-medical members and members of independent institutions, all of whom
will independently review the research.o

53.

CURE COMMITTEE REPORT, supra note 49, at 25

54. Id. at 32.
55.

Id.at 24.

56.

Id.

57.

Id.

58.

Id.

59.

Id. at app. 1, at 48.

60.

Id. at app. 1, at 44.
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The China-UK Research Ethics (CURE) Committee Report noted that the
quality of ECs in China varied in comparability to U.S. institutions, with the
ECs in Beijing and Shanghai offering the highest overall protections to
human subjects, while some institutions in smaller municipalities lagged
behind. 6 1 Generally, institutions that ranked highly in their fields also had
the highest standards for selecting ECs. 62 International accreditation has
already been granted to many hospitals throughout China for their culture of
patient safety. 63 The Joint Commission International (JCI) 64 lends
accreditation to the entire hospital, and the College of American Pathologists
lends accreditation to laboratories.
C. PediatricResearch

Following the European and United States encouragement of pediatric
pharmaceutical research in the late 1990s, the 2003 Good Clinical Practice
(GCP) Guidelines permitted drug manufacturers to enroll children in closely
monitored clinical drug trials.65 Article XIV (F) of the 2007 Biomedical
61.

Id. at 15.

62.

See id at 17.

63. Chinese Hospitals with full hospital-wide accreditation include: Beijing United
Family Hospital and Clinics, Beijing; Clifford Hospital, Guangzhou, Guangdong
Province; HOME Women's and Children's Hospital (Shenzhen), Shenzhen City,
Guangdong Province; Huashan Hospital, Fudan University, Shanghai; Jian Gong
Hospital (Health Palace Hospital), Beijing; Luoyang Orthopedic-Traumatological
Hospital of Henan Province, Luoyang, Henan Province; NJ HSCB Obstetrics and
Gynecology Hospital, Nanjing, Jiangsu Province; Shanghai Children's Medical Center,
Shanghai; Shanghai United Family Hospital and Clinics, Shanghai; QingHai Red Cross
Hospital, XiNing, QingHai; Sir Run Run Shaw Hospital, Hangzhou Zhejiang Province ;
TEDA International Cardiovascular Hospital, TEDA, Tianjin; Tianjin Ninghe Hospital,
Tianjim City; Yanhua Hospital, and Beijing; Zhengzhou People's Hospital. Zhengzhou,
Henan Province. JCI Accredited Organizations, JOINT COMM'N INTERNATIONAL,
(filter
http://www.jointcommissioninternational.org/JCI-Accredited-Organizations/
"Country" drop down for "China").
64. The JCI accreditation process is designed to "create a culture of safety and
quality within an organization that strives to continually improve patient care processes
and

results."

JOlNT

COMM'N

INTERNATIONAL,

http://www.jointcommission

international.org (last visited Jul. 17, 2012).
65.

Zhiping Li & Yi Wang, Drug Therapy for Children in China, 11 PEDIATRIC

DRUGS 16, 16 (2009).
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Research Involving Human Ethics Review Principles states that children,
pregnant women, the mentally handicapped, mental patients, prisoners, poor,
and less educated persons should be given 'special protections' by the
reviewing ethics committees. 66
The 1998 Interim Regulation for Ethical Review of Biomedical Research
Involving Human Subjects ("Interim Regulation") in China requires written
informed consent from competent human subjects in advance of biomedical
research. 67 Article 9 of the Interim Regulation bars children from
participation in the same research as adults without written consent from the
parent or guardian of each child; however, the child's choice to not
participate in research invalidates parental consent. Possible harm or risk
to children must also be minimized, and therapeutic research efficacy shall
not be lower than existing therapies.69
D. Factorsto Consider When Evaluating the Impact of Chinese Research

Although there are 400 million children in China, the country is home to
only 60,000 pediatricians and only four pediatric pharmacologists. 70 This
number is alarming, particularly since the number of pediatric trials being
conducted in China is rising each year. China also lacks clear sanctions for
violating ethical regulations governing human research. 7' Moreover, the
research-conducting institutions are largely responsible for monitoring and
72
73
Due to these
self-enforcing adherence to guidelines and regulations.
factors, research conducted in China may be held to varying levels of ethical
safeguards. 7 One of the key issues frequently brought up in literature

66.

CURE COMMITrEE REPORT, supra note 49, at app. 1, at 48.

67.

Id.

68.

Id.

69.

Id.

70.

Li & Wang, supra note 65, at 16.

71.

CURE COMMITTEE REPORT, supra note 49, at 31.

72.

Id. at 8.

73.

Id.

74.

Id. at 23.
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regarding ethical regulations of Chinese medical treatment is the approach to
familial decision making and the effect it has on how informed consent is
obtained in medical research and treatment, which we will later explore in
greater detail.75
Although the number of clinical trials in China is not yet on par with the
76
United States or Europe, it continues to increase significantly each year.
In 2008, the contract research organization (CRO) market was estimated to
be worth $250 million.77 The market value of CROs in China was $2.6
billion in 2010.78 Those numbers are even more impressive considering that
the CRO market in China only developed in the 1990's. 7 9 China offers
readily accessible human subjects, principal investigators with extensive
experience with Western pharmaceutical companies, s0 and the costs of
developing a drug in China are only 20% of the costs to develop one in the
Furthermore, China is a very large potential consumer
United States.
market, because China is home to approximately 1.5 billion people, or
roughly one-fifth of the world's population.
According to Dennis Gillings, CEO of Quintiles Transnational, while the
United States and Europe continue to dominate contract research (with 88%
of the global market as of 2006), growth in the share of Chinese market
value is anticipated to grow to many times beyond its current share by

75. Wang & Henderson, supra note 45, at 1876; see also Daniel Fu-Chang Tsai,
How Should Doctors Approach Patients?:A Confucian Reflection on Personhood,27 J.
MED. ETHICS 44, 48 (2001), available at http://jme.bmj.com/content/27/1/44.full.pdf+
html [hereinafter A Confucian Reflection on Personhood].
76.

JENNIFER ZAINO, WIPRO, THE STATE OF GLOBAL CLINICAL RESEARCH TRIALS

(2011), http://www.wipro.com/Documents/TW 1108035_StofClinTrials_REV vl.pdf.
77.

Hayduk et al., supra note 46, at 8.

78. China Contract Research Organization (CRO) Industry Report, 2010-2011, PR
NEWSWIRE, (Aug. 18, 2011), http://www.bizjoumals.com/prnewswire/press releases/
2011/08/18/NE54360.
79.

Hayduk et al., supra note 46, at 8.

80.

Id.

81.

Yibing Zhou, Bioplan Associates, Inc., Contract Research Drives China's

Pharma Sector, PHARMAMANUFACTURING.COM,

http://www.pharmamanufacturing.com/

articles/2006/158.html?page=1 (last visited Oct. 3, 2012).
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2030. 82 Growing numbers of global pharmaceutical companies are
establishing research and development centers in China, including Novo
Nordisk, AstraZeneca, Eli Lilly, Roche, and Pfizer. 83
E. Tension Between Imported Guidelines and Domestic Culture

Various guidelines for human subjects protection in research are
superficially quite similar to those in the United States, but substantial
cultural differences should be taken into account when considering how
research should be conducted in China. The most striking of these cultural
differences related to health care may be the practice of familial consent.
Individual informed consent is required in all clinical trials in China in the
same manner it is in the United States, but in China, consent of the family
and sometimes even the community is often also sought, at least in clinical
matters. 84 In the United States, standards for clinical research focus on the
beneficence, autonomy, non-maleficence, and justice principles, with liberty
and rights of the individual as a central focus of ethical considerations and
decision making. 85 Conversely, Chinese culture has been strongly
influenced by Confucian philosophy since the Han dynasty (206 BC-220
AD). 8 6 In fact, the Chinese had a written code of medical ethics as early as
the 7th century, written by Sun Szu-miao.
This code identified
8 8 "three
classical Chinese virtues: humanness, compassion, and filial piety."
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See CONFUCIAN BIOETHICS (Ruiping Fan ed., Kluwer Academic Publishers

2001); Xiaoyang Chen & Ruiping Fan, The Family and Harmonious Medical Decision
Making: Cherishing an Appropriate Confucian Moral Balance, 35 J. MED. & PHIL. 573
(2010); Yali Cong, Doctor-Family-Patient Relationship: The Chinese Paradigm of
Informed Consent, 29 J. MED. & PHIL. 149 (2004); Daniel Fu-Chang Tsai, The Bioethical
Principles and Confucious' Moral Philosophy, 31 J. MED. ETHics 159 (2005); A
Confucian Reflection on Personhood,supra note 75, at 44.
85.

See generally TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF

nIOMEDICAL ETHICS (4th ed. 1994).
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See generally Cheng-tek Tai & Lin, supra note 25, at 52.
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Confucians may view autonomy to be just as important as Western
bioethicists; however, autonomy is viewed as "collective rather than
individualistic."8 9 Confucian tradition views a community as starting with
the family unit, rather than the individual, and therefore autonomy may be
seen as a "collective right rather than individual privilege., 90 Confucianism
has provided the primary Chinese social, moral, political, and educational
philosophy for centuries, including the framework for China's longstanding
tradition of mediation rather than litigation. Confucius's idea of "persons"
was "best interpreted via his theories of 'chun-tze,' (the morally ideal
person), encapsulating a two-dimensional approach, (the 'autonomous
person' and the 'rational person.')." 91 A "Confucius understanding of
personhood encompasses the western concepts of free will and rationality,
which provide strong support for informed consent techniques," but
"Confucian concepts of personhood are balanced with a strong relational
perspective or 'horizontal dimension' with specific responsibilities to
others." 92
As recently as 1955, Tsai reminds us, Szasz and Hollender 93 proposed
models of physician-patient relationships based on different levels of
capacity in decision making: the activity-passivity model (similar to parentinfant communication); the guidance-cooperation model (similar to a parentadolescent child communication); and the mutual participation model
(similar to an adult-adult communication). 9 4 These were later replaced by
models such as the one proposed by Beaucham and Childress which put a
stronger focus on autonomous decision making. Tsai explains:
When a doctor approaches his patient, he sees a person not only as
a moral agent with autonomy and dignity to be respected, namely,
the patient's concerns, preferences and choices to be respected and

89.

Id. at 52.

90.

Id.

91. A Confucian Reflection on Personhood,supra note 75, at 44.
92.

Olsen, Wang, & Pang, supra note 24, at 180 (emphasis added).

93. See T. S. Szasz & M. H. Hollender, A Contribution to the Philosophy of
Medicine, 97 ARCH. INTERNAL MED. 585 (1956).

94. Id. at 590.
95.

See generally BEAUCHAMP & CHILDRESS, supra note 85.
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his rights protected. He also sees the patient as a relational being
with certain family, community and social-historical contexts: a
small self-encompassed by one or many greater selves. In a
Confucian context, the family, more than the individual, is often
considered as one basic unit in the two aspects of doctor-patient
relationships. Medical ethical decision-making tends to respect
the opinions and decisions made or agreed to by the family as a
whole. Given the concept of relational personhood, the emphasis
on family values, the large role and responsibility family usually
take in caring for sick persons, and the interconnectedness and
interdependence between family members, families must be taken
seriously. 96
While many of the ethical questions related to personhood and autonomy
interpretations in China arose out of clinical care rather than research, the
principles of autonomy related to research are similar. In fact, the ethical
issues may be even more pressing in terms of research subjects. Most
subjects will have time to solicit consent/assent from their families prior to
consenting, since research-related decisions are typically not as urgent as
clinical care decisions. Multiple federal guidelines are in place in China
which collectively represent a more Western approach to autonomous
individual consent in clinical research. However, in reference to research,
it is unlikely that the process of gathering consent is completely void of any
influence of traditional Confucian familial cultural norms.
Much of the Chinese bioethics literature on the topic of familial
assent/consent refers to the culturally appropriate balance of seeking to
obtain individual consent and familial assent. 98 Familial assent is
particularly important when dealing with rural and less educated Chinese
communities. It should be noted that this extra procedural step of familial
assent, when used with individual consent of the participant, may not always
be viewed in a negative light when conducting collaborative research. The
World Health Organization (WHO), in its Research Ethics Review
Committee (ERC) Information for Researchers Concerning Informed
Decision Making, Section IV, endorsed familial assent. However, one
cannot gloss over the impact this may have on pediatric and adolescent care

96.

A Confucian Reflection on Personhood,supra note 75, at 48.

97. See generally Clinical Trials in China, RJS MEDICAL TECHNOLOGY INC.
http://www.sfdachina.com/info/91-1.htm (last visited Nov. 12, 2012); see also CURE
COMMITTEE REPORT, supra note 49.
98.

See sources cite, supra note 84.
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and research, including the increased probability that a child will be
persuaded by the family.
F. Enforcement of Chinese Research Guidelines and Ramificationsfor
Noncompliance

The specific substantive protections embodied in 45 C.F.R. § 46 are also
embodied in the 2007 Regulations promulgated by the MOH. The 2007
Regulations state that violations by individuals or institutions will be
punished. These punishments vary but include "open criticism," withdrawal
or termination of positions, and withdrawal or termination of qualifications
to perform professional work. 99 These punitive measures fall short of the
more severe punishments under U.S. law, which may include criminal
charges.
G. Improving Evidence Based Medicine and Research in China

Uneven regional development is one of the challenges to improving
evidence-based medicine and research in China. In Beijing and Shanghai,
for example, researchers can search medical literature for free at their
university using popular international databases. 100 Physicians in more
remote locations, however, may be inhibited by a lack of available resources
and a more limited knowledge of English, possibly preventing the use of the
best evidence in their research or clinical care. 101 An additional problem for
Chinese researchers is that major medical journals lack clinical evidence
originating in China.1 0 2 In a recent article by Jiyao Wang, the author states:
from 1999 to 2008, 1880 clinical research articles were published
in The New EnglandJournalof Medicine, The Lancet, and JA MA4.

However, only 0.21% of these were from mainland China. Wu
and colleagues 103 analyzed randomized trials on 20 common
diseases published in China's natural knowledge infrastructure

99.

CURE COMMITTEE REPORT, supra note 49.

100.

Jiyao Wang, Evidence-based Medicine in China, 375

101.

Id.

102.

Id.

LANCET 532,

532 (2010).

103. Id. (citing T. Wu, Y. Li, Z. Bian, G. Liu & D. Moher, Randomized Trials
Published in Some Chinese Journals: How Many are Randomized?, 10 TRIALS 46
(2009)).
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database from 1994 to 2005, and found that only 7% of them met
methodological criteria (according to Cochrane review criteria).
Frequent errors in statistical analyses are also found in Chinese
medical journals, which reduces the credibility of the evidence.1
There is also credible evidence that improving the quality of local medical
research, as well as publishing the research, would improve best clinical
practices in many remote areas in China and beyond, as uncovered by a
recent survey involving China, India, and Kenya. o0 A PubMed search for
clinical research articles from 2000-2009 from China, published nationally
or internationally, found that published articles regarding clinical research
from China increased an average of 22% per year. 1o6 Additionally, most
well-run clinical trials are pharmaceutical pre-marketing trials due to a lack
of other funding for randomized trials.' 0 7 Wang appropriately suggests that
so many sponsored trials could result in publication bias for those
products. 8
H. Evaluating Chinese Research Regulations

The remarkable similarities between Chinese and U.S. regulations for
research involving human subjects and children provide an adequate basis
for collaborative and contracted research between the United States and
China if strict enforcement of these guidelines can be assured. It is clear that
the primary principles of "ethical" research and informed consent practices
are present in both systems, although consent is traditionally interpreted
differently by country. The explosive growth in the CRO market in China
also raises concerns that enforcement of guidelines may not be developing
quickly enough to protect human subjects in some regions.
We believe the societal focus on the family in China's practice of
obtaining consent and assent reflects Chinese society the same way the
individual-centric focus of U.S. regulations for consent and assent reflect
American society. Because no two societies are identical, as Emanuel

104.

Id.

105. J. Page, et al. Attitudes of Developing World Physicians to Where Medical
Research is Performedand Reported, 3 BMC PUBLIC HEALTH 6 (2003).
106. Yonghua Hu et al., Status of ClinicalResearch in China, 377 LANCET 124, 124
(2011).
107.

Wang, supra note 100, at 532.

108.

Id.
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pointed out in The Benchmarks of Ethical Research, "differences in ...

social traditions and practices make the process of informed consent in
developing countries complex."' 10 9 Understanding the cultural context in
which decisions are traditionally made will better ensure that ethics
regulations will be both protective of subjects and culturally sensitive to the
populations those regulations are intended to serve.
VI. INTRODUCTION TO REGULATIONS IN KENYA

The National Council for Science and Technology (NCST) is responsible
for coordinating all research in Kenya and advising the government on
research-related matters. NCST also makes final decisions about protocol
applications in Kenya. 1o Two other national bodies involved in ethical
review are the Kenya HIV/AIDS Vaccine Subcommittee and the Pharmacy
and Poisons Board, both of which are affiliated with the MOH."' Through
this government oversight, Kenya developed three fundamental documents
promulgating human subjects research guidelines.
First, NCST promulgated Guidelines for Ethical Conduct of Biomedical
Research Involving Human Subjects in Kenya, pursuant to the Science and

Technology Act of 1979. 112 These guidelines set forth a framework for
determining if a research proposal is ethical with respect to the following
factors: value, scientific validity, fair subject selection, favorable risk-benefit
ratio, independent review, informed consent and respect for potential and
enrolled subjects." 3
Second, the Kenya Medical Research Institute (KEMRI) has guidelines
for research that will be conducted through that institution. KEMRI was
established as an Amendment under the 1979 Science and Technology Act

109. Ezekiel J. Emanuel et al., What Makes Clinical Research in Developing
Countries Ethical? The Benchmarks of Ethical Research, 189 J. INFECTIOUs DISEASES
930, 934 (2004).
110. NAT'L COUNCIL FOR SCI. AND TECH., NCST No. 45, GUIDELINES FOR ETHICAL
CONDUCT OF BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS IN KENYA 2, 3, 10
(2004) (Kenya) [hereinafter GUIDELINES FOR ETHICAL BIOMEDICAL RESEARCH]; see also
Science and Technology Act of 1980, ch. 250 art. 3-5 (Kenya).

111. MINISTRY OF HEALTH, KENYA NATIONAL GUIDELINES FOR RESEARCH AND
DEVELOPMENT OF HIV/AIDS VACCINES 20, 23, 25 (2005) (Kenya).
112.

GUIDELINES FOR ETHICAL BIOMEDICAL RESEARCH, supra note 110.

113.

Id.at2-9.
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to be a national body responsible for implementing health science
research. 114
Third, in 2005, the MOH enacted National Guidelinesfor Research and
Development of HIV/AIDS Vaccines. These guidelines specifically address

human subjects research proposals relating to the effort to identify
HIV/AIDS vaccines.1
A. The Applied Process ofEthicalReview in Kenya

Kenya has a multi-tiered review system for human subjects research.
Research roposals must generally go through two to three reviews before
approval. RDepending upon local requirements, some proposals must first
be reviewed by the researcher's department within the local institution.117
Then the ethical review committee at the host institution where a local
researcher is based or where a foreign researcher is collaborating must
review the proposal. 11 Once this review is completed, a review is
performed by the NCST. 119 Researchers not affiliated with a specific
institution or affiliated with an institution that lacks an ethical review
committee petition directly to NCST for review. 12 0
While researchers typically must seek final approval from NCST, certain
institutions have final approval power themselves. KEMRI and Kenyatta
National Hospital maintain committees with final approval power. 121 These
114.

Science and Technology Act, supra note 110.

115. KENYA NATIONAL GUIDELINES FOR RESEARCH AND DEVELOPMENT OF HIV/AIDS
VACCINES, supra note 111, at 23-27.

supra note 110,

at 2, 3, 10.

116.

GUIDELINES FOR ETHICAL BIOMEDICAL RESEARCH,

117.

Id.

118.

Id.

119.

Id.

120.

E-mail from Pauline Mwinzi to David Borasky (Feb. 6, 2006) (on file with

author); E-mail from Pauline Mwinzi to Kelly Safreed Harmon (Feb. 21, 2006) (on file
with author).

121. C. S. Molyneux et al., 'Even if they ask you to stand by a tree all day, you will
have to do it (laughter). . . !': Community Voices on the Notion and Practiceof Informed
Consent for Biomedical Research in Developing Countries, 61 Soc. SC. & MED. 443,
444-45, 450 (2005).
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hospital ethical review committees are responsible for reviewing all research
proposals from MOH researchers.1 22
For HIV/AIDS vaccine research, investigators must submit a conce t
paper to the Kenya HIV/AIDS Vaccine Subcommittee seeking approval.
The investigators must next submit a proposal simultaneously to the
Pharmacy and Poisons Board and to NCST or another designated ethical
review committee. Both of those bodies must approve the research plan. 124
Enforcement of these stipulations is always a concern, especially as it
relates to ethical research considerations in pediatrics. All three of the
guidelines described above are legally binding and enforceable, as they have
been promulgated through acts of Parliament. 12 In addition, KEMRI has a
disciplinary committee 2to ensure that the agency's research complies with all
relevant requirements.1 6
B. The Issue ofInternationalPediatricResearch Ethics Guidelines

Since the vast majority of clinical research pertaining to children in Kenya
is in collaboration with international sources, issues often arise due to
differing viewpoints regarding appropriate ethical and procedural issues. As
discussed above, current Kenyan research guidelines are not in alignment
with many international jurisdictions, including the United States, United
Kingdom, and Europe. This raises several pertinent questions for any
researcher involved in international research, including: how should
consensus be reached when clear consensus may not be present within a
single country?, and when collaborating partners have different ideas about
appropriate ethical standards,-in this case, ethical issues in pediatric
research-how should those differences be resolved? To best resolve these
issues, a comparison of ethical issues surrounding pediatric research will be
detailed, first with the state of pediatric research in the United States,
followed by a review of the state of pediatric research in Kenya.

122.
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125.
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C. Current State ofPediatricResearch Ethics in Kenya

Kenya is a developing country undergoing a major health crisis primarily
due to a combination of extreme poverty, poor sanitation, and high rates of
HIV/AIDS infection. As such, Kenya has not enjoyed the innate wealth and
scientific ability necessary to be on the forefront of full legislative protection
of children in research initiatives. Nonetheless, one key issue pertaining to
research ethics and children in Kenya is proper informed consent. Studies
have clearly defined this problem, one of which is multi-factorial in
etiology. 127In a qualitative study examining opinions of Kenyan community
members related to informed consent for research, Molyneux et al. asked
community focus groups whether consent should be sought from Kenyan
They reported
children from whom blood samples would be requested.
that all of the groups "reacted with surprise" to the question of considering
consent for children, with "general agreement that children should not be
asked," and they further specified that investigators should not consider
asking children aged ten to twelve years.129 The study participants reported
concerns that the children could not "reason things out" or understand why
samples were needed, and they felt that fear of pain would be the children's
only consideration. 130 Even for children aged ten to thirteen years, the
Kenyan community members felt that researchers should discuss the project
directly only with the parents, and then the parents could relay the
information to the children. 131 The practice of deferring consent to the
parents does not align with the Kenyan government's position.
The Guidelines for the Ethical Conduct of Biomedical Research Involving
Human Subjects published by the Kenya NCST support respect for the
dissent of pediatric research subjects, stating that when "the child refuses to
participate in the research, that refusal must be respected unless there's no
other medical alternative from which the child could benefit." 132 While
these guidelines do not specifically mandate pediatric assent, the clear
emphasis on respecting a child's dissent might suggest a similar position.
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Molyneux et al., supra note 121, at 444-45.
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These guidelines could also be interpreted as willingness to rely on implied
assent, assuming that active dissent was not voiced. The Kenyan government
realizes that appropriate pediatric informed consent is a key ethical
obligation for clinical studies, but empirical studies show that the key
requirements are often not met by community leaders. 133
D. The Dilemma - Closing the Apparent Gaps Between the Kenyan
Government andKenyan People in Regards to EthicalResearchfor the
PediatricPopulation

The application of voluntary informed consent is one element of ethically
sound clinical research. The difficulties of achieving genuine informed
consent in practice are widely recognized, particularly where research
involves children and in settings where investigators have significantly
different educational and socio-cultural backgrounds to study participants, 34
as in Kenya. To address this concern, one must first identify the causes of
the problem.
In 2004, the KEMRI examined perceptions, understanding, and
appropriateness of informed consent processes for pediatric research in lowincome settings of Kenya. 135 While every study and consent form was
reviewed in advance by independent national and international committees,
the views and understanding of the 'subjects' of these activities had never
been documented.1 3 6 The principal approach to exploring informed consent
("the consent study") was the use of three 'research case studies,' each of
which was a study that had been approved locally, nationally, and
The
internationally and was on-going at the time of the consent study.
findings highlighted a range of inter-related issues for consideration in future
study settings and beyond. Some of these issues include conceptual and
linguistic barriers to communicating effectively about research, the critical

133. C.S. Molyneux, N. Peshua, & K. Marsh, Understandingof Informed Consent in
a Low-Income Setting: Three Case Studies from the Kenyan Coast, 59 SOC. SCi. & MED.
2547, 2551 (2004).
134. Mark G. Kuczewski & Patricia Marshall, The Decision Dynamics of Clinical
Research: The Context and Process of Informed Consent, 40 MED. CARE V45, V45
(2002).
135.
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and complex role of fieldworkers and nurses in consent procedures, features
of research unit-community relations which affect these processes, and the
special sensitivity to certain issues such as blood sampling. 138 In sum, the
data identified in the study suggests that research messages in Kenya are lost
in the researcher-communicator-parent chain in both community-based and
in-patient studies.1 39
E. Working to Improve PediatricResearch Ethics Guidelines in Kenya

Despite the
Kenyan government enacting
legislation and
recommendations for protection of children in clinical research, other
factors, mainly socio-economic in nature, have prevented these
recommendations from being fully implemented.140 This is not uncommon
in developing countries, as evolution in research protections are gradual
processes. It starts with government implementation and trickles downward
thereafter throughout the sovereign. Emanuel et al. have developed a
framework for ethical clinical research in developing countries that includes
collaborative partnership as a key principle for multinational clinical
research. 141 Among the benchmarks for this principle is respect for the
community's values, culture, traditions, and social practices.142 Based upon
these principles, we can address the current problem with ethical research
development in Kenya by targeting three inter-related themes: issues relating
to the concept and terminology for research, the role of communicators, and
the research unit-community power relations.
F. Conceptual and Terminology Issues

Many community members in rural Kenya are not familiar with the
concept of research, and there are no commonly used or universally
understood terms for "research." While the absence of more complex
research-related terms such as 'placebo,' 'genotyping,' and 'randomization'
is regularly referred to in the literature, this more basic point is given less
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attention. 143 Informal discussions with researchers suggest that staff are
generally not aware of the substantial communication barriers between
researchers and laypersons in discussing biomedical research. 144 In practice
therefore, the research message can often be lost early in the communication,
with the rest of the information, however detailed, not linked to research. 145
These concept and terminology problems may be resolved through improved
communicator fluency. 146
G. The Role of Communicators

Regardless of the wording on consent forms and explanations given to
fieldworkers by supervisors, the details disclosed and focused upon by
fieldworkers are heavily influenced by other factors such as self-perceived
parental interest in the information and the ability to understand it, the
fieldworkers' own understanding of the importance of the notion of
informed consent, the balance between risk and benefits, and time
pressures. 147 Fieldworkers often simplify research-related information from
forms, focusing on the practical details and benefits instead, in part because
of the above-mentioned complications. 14 Simplification and focusing on
benefits make sense: these aspects are easier to explain and are the primary
concern of potential participants. Benefits may also be "hyped up" for some
studies, or-as one researcher put it-"nuts and bolts" may be added. 149
Much of the ongoing pediatric clinical research in Kenya is of the upmost
importance in the lives of children whom may be recruited, because if they
are not recruited, they may die.150 Thus, the study benefits may become the

143.
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paramount focus in the fieldworkers' minds and the justification for attempts
to persuade subjects to join and remain in studies. This may, in part, be due
to a genuine overlap between clinical and research practice in much clinical
research, i.e., most ethical review committees require research benefits
outweigh the risks, and from clinician researchers' own moral and practical
perspective-they do. 151
While many of these notions may be interpreted negatively, the flipside is
that fieldworkers may minimize refusals based on misunderstandings, in
biomedical terms, of the associated risks, thereby ensuring that community
members do not miss out on study-specific benefits. It is worth mentioning
that these behaviors would be supported by many community leaders in
Kenya.152 While researchers should possess the notion of informed consent,
many community members in Kenya (particularly mothers with little formal
education) would find it difficult to understand and accept the
information. 153 As such, many researchers feel study details would actually
heighten confusion and concerns.154
H. Unit-Community Relations

Many documented comments by fieldworkers and parents in Kenya
suggest that feelings of trust, awe, fear, and anxiety play a significant role in
decision-making for joining studies, both in the field and in the hospital, and
lead to a considerable gap between disclosure and decision making. 155
related causes, due mainly to lack of access of retroviral treatment. The epidemic has
resulted in a sharp deterioration of basic health indicators. Between 1998 and 2003 - or
roughly between the epidemic's peak in Kenya and the early introduction of antiretroviral
therapy - the adult mortality rate (ages 15-49) rose by 40% for women and by 30%
among men. With a large number of newborns newly infected each year, the epidemic
has also increased mortality among children under five. See NATIONAL AIDS CONTROL
COUNCIL (NACC) & NATIONAL AIDS AND STI CONTROL PROGRAMME (NASCOP), THE
KENYA AIDS EPIDEMIC UPDATE 2011 (2012), available at http://www.unaids.org/
en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ceKENarrati
ve Report.pdf.
151.
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Regardless of what is actually said by the fieldworkers during the consent
process, many parents report that the Unit (or hospital) staff should just do
whatever they feel is right, or agree with what is told to them because there
may be unknown or unspecified benefits in the future. While the importance
of such psychosocial effects in informed-consent processes has been
observed in high-income countries,' 56 what make them particularly strong or
unique in a low-income setting is the nature of public sector-citizen
relations, and the overall perceptions of the role of the institution.
Inequitable doctor-patient relations have been observed in clinical settings
all over the world. In high-income countries, an egalitarianism has evolved,
partially as a result of an increasingly educated public and the threat of
lawsuits. Patients, therefore, ask more questions, are more likely to know
their rights, dispute a doctors' authority, and demand answers. In lowincome countries, like Kenya, relations in the public sector are more
paternalistic: many doctors communicate the least amount of information
possible to their patients. 1 While this may be expected and accepted, the
negative health worker behaviors that are so often reported are not. 1 Such
behavior is in large measure the outcome of drastic declines in real terms of
public sector salaries, which have led to demoralization, de-motivation, and
cynicism in many.159
The perceived influence that the Unit staff has in allowing community
members to access such benefits gives them significant power relative to
parents and patients.160 This is especially the case in the hospital setting,
where many parents express powerlessness upon arrival. 16 This was
156. S. C. Harth & Y. H. Thong, ParentalPerceptions and Attitudes About Informed
Consent in Clinical Research Involving Children, 40 Soc. ScI. & MED. 1573, 1574
(1995).
157. Marie-Pierre Priziosi et al., Practical Experiences in Obtaining Informed
Consentfor a Vaccine Trial in Rural Africa, 336 NEW ENG. J.MED. 370, 370 (1997).
158. Mary Travis Bassett et al., Professionalism, Patient Satisfaction and Quality of
Health Care: Experience During Zimbabwe's Structural Adjustment Programme, 45

Soc. SCI. & MED. 1845, 1847-48 (1997).
159. Malcolm Segall, From Cooperation to Competition in NationalHealth Systemsand Back?: Impact on Professional Ethics and Quality of Care, 15 INT'L J. HEALTH
PLANNING & MGMT. 61, 66 (2000).
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usually described as a relief: mothers had carried out a range of therapeutic
options before coming and undergone significant trouble and cost to reach
the hospital.162 Responsibility for the child was then handed over to experts
who were trusted to do whatever they could.163 These situations, previously
positive experiences of the hospital, or the Unit's reputation for handling
severely sick children, contribute to relatively strong feelings of trust and
awe in staff-community interactions. 6
Pediatric research guidelines in Kenya clearly demonstrate a common
ethical conundrum highly prevalent in global health research: the lack of
While it
consistency in applying ethically permissible informed consent.
is quite easy to sit in an Institutional Review Board (IRB) meeting and
design protections best suited to protect pediatric subjects from adverse
harm of a proposed study, protections made to maximize the informed
consent procedure are often blurred in the field. As detailed by review of
multiple studies, this problem has many causes.166 Disparities in education
and wealth between the researching nation and host nation, communication
problems, and varying ethical beliefs with respect to appropriate informed
consent procedures are just a few examples. 16 Coupled with these factors,
especially as it relates to impoverished nations such as Kenya, are the large
discrepancies in which different cultures view health care providers and
researchers.168 While America and other advanced nations often question
many aspects of health care research, a much more accepting and
paternalistic role of the health care provider exists in Kenya.
Morality of informed consent is context dependent. As applied from
academia and institutional review board meetings, deep understanding of the
subject's risks in the research is of the utmost significance. As applied to the
field researcher in a third world country where lack of education, extreme
poverty, and a paternalistic culture exists, the preeminent informed consent
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procedure is to tell as little 'medical' detail as possible so that the pediatric
child can get what is often life-saving treatment via enrollment in the
research study. Ethical principles surrounding the best manner for informed
consent are indeed flexible, as multiple variables interplay to form the best
health outcome, as well as the best perceived ethical and moral outcome.
VII. INTRODUCTION TO REGULATIONS FOR BIOMEDICAL RESEARCH IN
INDIA

The first guidelines for biomedical research in India were created by The
Indian Council of Medical Research. The Policy Statement on Ethical
Considerations involved in Research on Human Subjects was created in
1980 and was revised in 2000 as the Ethical guidelines for Biomedical
Research on Human Subjects. 169
Varied versions of international

biomedical research guidelines were released in 2002, and they included the
revised Council for International Organizations of Medical Science
(CIOMS) guidelines which focused on ethical norms relevant to research
participants in developing nations.170 CIOMS guidelines were prepared in
collaboration with the World Health Organization (WHO), and updated from
the previous version which was primarily related to externally funded
clinical trials taking place in low resource countries. 17' At that time, India
faced challenges with applying universal ethical principles to their
multicultural society due to the varying standards of healthcare systems.172
To address this issue, India released a third version of the Ethical Guidelines
for Biomedical Research on Human Particiants, known as the Indian
Councilfor Medical Research (ICMR) Code, consisting of two parts: (1)
Statement of General Principles on Research using Human Participantsin
Biomedical Research and (2) Statement of Specific Principles on Research
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using Human Participantsin specific areas of Biomedical Research.174 The

new version of the ICMR Code was created with the hopes of covering new
methods in biological sciences and biotechnology.' 75 While the latter part of
the ICMR Code is not the subject of this paper, nor are there specific
guidelines for pediatric research, it is helpful to know what areas of
biomedical research and healthcare contain specific provisions to inform a
comparative analysis. Part two of the ICMR Code provides specialized
guidelines for research in the following areas: human genetics and genomics
research; research in transplantation; research and evaluation of clinical
drugs; vaccines; devices; and research on epidemiological studies.176 In the
United States, no such specific research ethics provisions can be found
codified in the federal register, except for provisions under the FDA.177
Of particular interest is the flexibility of the statements, which according
to the ICMR may be amended, substituted, varied, or added to "from time to
time."178 The Indian research guidelines are meant to ensure that biomedical
research on human subjects maintains a valid purpose, is conducted
properly, and undergoes appropriate evaluation. This philosophical intent
behind the ICMR Code is virtually synonymous to the role of the
institutional review board, the C.F.R., and the Belmont Principles combined
when viewing these from an U.S. perspective.
A. The Indian Biomedical Research Ethics Guidelines-ThePhilosophical
and PracticalPrinciples

Similar to other guiding documents, the ICMR Code utilizes twelve
principles as its foundation for the ethical treatment of human subjects in
biomedical research. 17 9 What follows is a brief explanation of each of the
twelve ICMR Code principles, which in one way or another reflect the
traditional research ethics principles used in both the United States and
internationally.
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B. The Principle ofEssentiality

The principle of essentiality is meant to ensure that the selected research
subject is essential to conduct the research and lends to the mission of
advancing knowledge for human benefit. 180 In its present form, this
principle extends further to include the caveat that the research also benefits
the ecological and environmental wellbeing of the planet.'8 1 Extending the
principle of essentiality could have social, cultural, and religious ties to the
Indian people through the Hindu religion.
C. Principlesof Voluntariness,Informed Consent and Community
Agreement

The next principle actually includes several principles: the principles of
voluntariness, informed consent, and community agreement of the ICMR
Code. 182 These principles are consistent with documents such as the
Belmont Reportl8 and the United States Federal Research Regulationsl84
which include informed consent as a foundational principle in research
ethics. Like other guiding principles, this principle in the ICMR Code
maintains that research participants must be fully aware of the risk and
benefits of research and that the participant has the right to withdraw from
the research regardless of any obligations already entered into-including
The aspect of community in research participation differs
legal contracts.
in developing nations, including India. Where research entails treating any
community or group of persons, the ICMR utilizes the term mutatis
mutandis to explain that both the community and the individual person must
give a mutual consent to participate in the research and understand changes
of any particular relevance to all participants.'8 In addition, this ICMR
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principle of informed consent and voluntariness includes the provision that
when a fiduciary duty applies, the manner of consent may also include one
person consenting for another.
D. The PrincipleofNon-Exploitation

The next principle elucidated in the ICMR is the principle of nonexploitation1 which, as a general rule, suggests that research participants
are compensated for their involvement in the research, kept informed of all
continuing risks and benefits of the research regardless of economic or
health literacy status, and that research participant selection does not
discriminate in any arbitrary manner. 189 In the ICMR Code, this principle of
non-exploitation goes further to include an insurance requirement that each
research protocol will include a built-in mechanism for compensation for the
human participants that covers all foreseeable and unforeseeable risks by
providing remedial action including comprehensive aftercare, treatment preand post-research, and immediate rehabilitative measures for those
affected. 190
E. The Principles ofPrivacy and Confidentiality

The next principle in the ICMR Code includes both universal principles of
privacy and confidentiality. The principles of privacy and confidentialityl91
reflect the general privacy requirements in all areas of medical practice in
the United States. This ICMR Code principle requires adherence to privacy
and non-disclosure practices while dealing with medical information when
the identity and records of the human participants of the research are
utilized. 19 Furthermore, this principle in the ICMR Code requires efforts to
eliminate potential stigmatization of research subjects for participating in the
research. '
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F. The PrinciplesofPrecautionand Risk Minimization

Minimizing risk to research participants is a universal goal,19 4 and the
ICMR Code elaborates on this fact through its next principles: precaution
and risk minimization. Like the United States, India has no means to truly
quantify research risks for consenting adults; however U.S. federal
guidelines require that a minimal risk standard is met for pediatric research
participants. 1 Approval for pediatric research studies requires that the
protocol offers participants the 'prospect of direct' benefit and research that
poses minimal risk or a minor increase over minimal risk.196
G. Principlesof the Maximization of the Public Interest and Distributive
Justice

In the ICMR Code, the principles of maximization of public interest and
distributive justice reflect the idea that research should also benefit mankind
as a whole.1 97 The community involvement principle instructs that there
should be direct benefit to the community from which research participants
are drawn, and India exemplifies this principle. In the United States, this
trend is seen in Community Based Participatory Research (CBPR). CBPR is
a model of research which values the role of community members and
academicians as equitable partners. In CBPR, each partner makes unique
contributions to the research process.198
Specific research methodology used in CBPR varies widely. Generally,
however, CBPR projects value cooperative efforts between community
members and researchers. Moreover, they strive to utilize the study results
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to the benefit of the participating communities. 199 CBPR has gained
popularity in areas of research that focus on health disparities, as well as
with pediatric populations2.200 While it is common for pediatric populations
to be the subject of CBPR, it is often impractical to involve children and
201
adolescents in the research process.
While there are inherent challenges
with involving children and adolescents in the details of the research
process, community involvement is an important principle in biomedical
research illustrated by both the United States and India.
H. PrinciplesofInstitutionalAgreements and Public Domain

The ICMR Code specifies that research protocols contain specific
institutional agreements and allow for dissemination of research results into
the public domain.202 There is virtually no difference between these Indian
principles and the general requirements for researchers and federal grant
applications in the United States. The implications of adhering to these
research principles allow for a transparent research process within multiple
collaborators.
I. Principlesof Total Responsibility and Compliance

The final two principles in the ICMR Code presume a total responsibility
requirement for the researchers to maintain due diligence and to affirm a
positive duty of compliance.203 Perhaps redundant in substance, yet distinct
in language, these principles conclude with expressions relating to the
binding nature of the Indian Biomedical Research Ethics Guidelines on
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researchers and institutions involved. 204 In the United States, research
compliance is enforced by regulatory agencies with many full-time
institutional employees dedicated to the protection of human subjects in

research.

205

J. Research Review Proceduresin India-InstitutionalEthics Committees

Similar to the U.S. IRBs, multidisciplinary Institutional Ethics
Committees (lECs) evaluate risk in research protocols in India. 206
Unfortunately, the ICMR Code is not legally binding. Thus, the urgentv
needed legal force to prevent exploitative research is unavailable. 2
Additionally, IECs and IRBs are responsible for continuing review of
protocols, which must accord with the Standard Operating Procedures of the
World Health Organization (WHO). 208 Without mandatory accreditation
and registration of IECs, it is difficult to ensure that they are protecting
human subjects. Recently, many IECs voluntarily joined accreditation
through the Forum for Ethical Review Committees in the Asian and Western
Pacific Region (FERCAP), and the Association for the Accreditation of
Human Research Protection Programs, Inc. (AAHRP). 209 The increased
utilization of CROs 210 has caused critics to speak to the need for reform to
the policies and procedures IECs follow in India.
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VIII. CONCLUSION

Developing countries have taken steps to create comprehensive guidelines
to direct human subjects research, but it is striking that there are very few
guidelines specific to the inclusion of children and adolescents in research.
While permissible in each country, their status as a "special" or a
"vulnerable" population may be identified, but there is little concrete
identification of what, if anything, that status guarantees.
The challenge of each of these developing countries is quite different. In
China, guidelines for research, in general, are very similar to the U.S.;
however, it is not clear that those guidelines are properly enforced.
Moreover, key differences remain, such as China's tradition of familial
assent for medical decision-making. In Kenya, the treatment of children is
so closely related to research that families do not always understand that
they are participating in research and rarely question doctors' advice.
Finally, in India, subjects would be better protected if guidelines were
enforced. However, due to the large population, India should focus on
bioethics education, good clinical practice, and pharmacovigilance, which
will lead to increased transparency in biomedical research. By better
understanding the guidelines and cultural contexts of developing countries,
research quality and international collaboration can improve.

